Related Experiment Video
Updated: Sep 20, 2025

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
Recent advances in the treatment of advanced prostate cancer: maximizing existing therapies while searching for novel
1Division of Hematology Oncology, Department of Medicine, Medical University of South Carolina, Charleston, South Carolina, USA.
Purpose Of Review:
Present highlights from recent research examining treatment of advanced prostate cancer.
Recent Findings:
Data are emerging that combining androgen deprivation, docetaxel, and additional androgen-receptor-targeted therapies in treatment naïve metastatic prostate cancer may be an effective strategy to improve outcomes. Genomically targeted therapies and radiopharmaceuticals continue to be evaluated in the treatment of advanced castration-resistant prostate cancer.
Summary:
Although no clear consensus has emerged regarding the best sequencing of available therapeutics, trial results continue to support moving available therapies earlier in the disease course. Data continue to build for novel radiopharmaceuticals soon to likely be approved for treatment of castration-resistant disease.
Insights
Combining therapies like androgen deprivation and docetaxel shows promise for metastatic prostate cancer. Novel radiopharmaceuticals are also emerging for advanced castration-resistant prostate cancer treatment.
Area of Science:
- Oncology
- Urology
Background:
- Advanced prostate cancer treatment is evolving rapidly.
- New therapeutic strategies are under investigation.
Purpose of the Study:
- To review recent research on advanced prostate cancer treatments.
- To highlight emerging therapeutic combinations and agents.
Main Methods:
- Review of recent clinical trial data.
- Analysis of emerging treatment strategies for prostate cancer.
Main Results:
- Combining androgen deprivation, docetaxel, and androgen-receptor-targeted therapies may improve outcomes in treatment-naïve metastatic prostate cancer.
- Genomically targeted therapies and radiopharmaceuticals are being evaluated for advanced castration-resistant prostate cancer.
Conclusions:
- Evidence supports earlier use of available therapies in advanced prostate cancer.
- Novel radiopharmaceuticals are anticipated for castration-resistant disease treatment.
More Related Videos
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Treatment Resistant Cancers
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Tumor Immunotherapy

